News & Views - Page 20 of 53 - Telix Pharmaceuticals Limited

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation process

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May 2021

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging product.

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG

AUDIO LINK NOT INCLUDED – Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

Telix FY2020 Results and Company Update Conference Call

Telix to present the Company’s FY2020 results together with an update on Telix’s operations.

Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Telix announces the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorization allowing the use of TLX591-CDx

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic oncology.